Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Feldman Paul L, holds the title of Chief Scientific Officer at Aktis Oncology, Inc..
On 2026-11-18, the insider transacted 55,035 shares.The shares were transacted at a weighted average price of $1.90 per share, resulting in a total market-relevant value of $105K.
Feldman Paul L (Chief Scientific Officer) exercised options for $105K of $AKTS
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.